Le Lézard
Classified in: Covid-19 virus
Subject: ATY

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates The Walt Disney Company's Directors and Officers for Breach of Fiduciary Duties - DIS


NEW YORK, July 23, 2020 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, is investigating certain directors and officers of The Walt Disney Company ("Disney") (NYSE: DIS) for breaching their fiduciary duties to Disney and its shareholders.  If you are a Disney shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected].

Scott+Scott is investigating whether Disney's board of directors or senior management failed to manage Disney in an acceptable manner, in breach of their fiduciary duties to Disney, and whether Disney has suffered damages as a result.  Specifically, Scott+Scott is investigating potential breaches of fiduciary duty regarding 1) systemic racial discrimination and bias at Disney; and 2) prematurely and inappropriately reopening Disney theme parks during the COVID-19 outbreak.

What You Can Do
If you are a Disney shareholder, you may have legal claims against Disney's directors and officers.  If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or [email protected]

About Scott+Scott
Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States.  The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.

Attorney Advertising

CONTACT:
Joe Pettigrew
Scott+Scott Attorneys at Law LLP 
230 Park Avenue, 17th Floor, New York, NY 10169
844-818-6982
[email protected]

SOURCE Scott+Scott Attorneys at Law LLP


These press releases may also interest you

at 02:30
Allied Market Research published a report, titled, "Pension Administration Software Market by Component (Solution and Services), Deployment Mode (On-Premise and Cloud), Type (Public Pension and Private Pension), End User (Employers, Pension Plan...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:05
Teck Resources Limited (Teck) today announced its unaudited first quarter results for 2024. "All outstanding major construction at our QB operation was completed in the first quarter, including the shiploader and molybdenum plant, and we marked the...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...



News published on and distributed by: